Orazio Caffo, Ugo De Giorgi, Lucia Fratino, Daniele Alesini, Vittorina Zagonel, Gaetano Facchini, Donatello Gasparro, Cinzia Ortega, Marcello Tucci, Francesco Verderame, Enrico Campadelli, Giovanni Lo Re, Giuseppe Procopio, Roberto Sabbatini, Maddalena Donini, Franco Morelli, Donata Sartori, Paolo Zucali, Francesco Carrozza, Alessandro D'Angelo, Giovanni Vicario, Francesco Massari, Daniele Santini, Teodoro Sava, Caterina Messina, Giuseppe Fornarini, Leonardo La Torre, Riccardo Ricotta, Michele Aieta, Claudia Mucciarini, Fable Zustovich, Sveva Macrini, Salvatore Luca Burgio, Sandra Santarossa, Carmine D'Aniello, Umberto Basso, Sara Tarasconi, Enrico Cortesi, Consuelo Buttigliero, Fiorella Ruatta, Antonello Veccia, Vincenza Conteduca, Francesca Maines, Enzo Galligioni
BACKGROUND: The availability of new agents (NAs) active in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel treatment (abiraterone acetate, cabazitaxel, and enzalutamide) has led to the possibility of using them sequentially to obtain a cumulative survival benefit. OBJECTIVE: To provide clinical outcome data relating to a large cohort of mCRPC patients who received a third-line NA after the failure of docetaxel and another NA...
July 2015: European Urology